Dosing & Uses
Dosage Forms & Strengths
injectable solution
- 50mg/mL
tablet
- 50mg
tablet, chewable
- 50mg
Prevention of Motion Sickness
50-100 mg PO/IV/IM q4-6hr PRN, 30 minutes before exposure to motion; not to exceed 400 mg/day
Meniere's Disease (Off-label)
25-50 mg PO q8hr for maintenance
50 mg IM for acute attack
Administration
IV: 50 mg in 10 mL NS over 2 minutes
Dosage Forms & Strengths
injectable solution
- 50mg/mL
tablet, chewable
- 50mg
tablet
- 50mg
Prevention of Motion Sickness
General dose: 1.25 mg/kg or 37.5 mg/sq.meter IV/IM q6hr; not exceed 300 mg/day
2-6 years old: 12.5-25 mg PO q6-8hr; no more than 75 mg/day
6-12 years old: 12.5-25 mg PO q6-8hr; no more than 150 mg/day
>12 years old: Same as adult dosing
Prevention of Motion Sickness
50-100 mg PO/IV/IM q4-6hr PRN, 30 minutes before exposure to motion; not to exceed 400 mg/day
Meniere's Disease (Off-label)
25-50 mg PO q8hr for maintenance, 50 mg IM for acute attack
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (7)
- calcium/magnesium/potassium/sodium oxybates
dimenhydrinate, calcium/magnesium/potassium/sodium oxybates. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
- eluxadoline
dimenhydrinate, eluxadoline. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Avoid coadministration with other drugs that cause constipation. Increases risk for constipation related serious adverse reactions.
- metoclopramide intranasal
dimenhydrinate, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.
- olopatadine intranasal
dimenhydrinate and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- pitolisant
dimenhydrinate decreases effects of pitolisant by Other (see comment). Avoid or Use Alternate Drug. Comment: Pitolisant increases histamine levels in the brain; therefore, H1 receptor antagonists that cross the blood-brain barrier may reduce the efficacy of pitolisant.
- secretin
dimenhydrinate decreases effects of secretin by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Concomitant use of anticholinergic drugs may cause a hyporesponse to stimulation testing with secretin. Discontinue anticholinergic drugs at least 5 half-lives before administering secretin.
- sodium oxybate
dimenhydrinate, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.
Monitor Closely (211)
- acrivastine
acrivastine and dimenhydrinate both increase sedation. Use Caution/Monitor.
- albuterol
dimenhydrinate increases and albuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- alfentanil
dimenhydrinate and alfentanil both increase sedation. Use Caution/Monitor.
- alprazolam
dimenhydrinate and alprazolam both increase sedation. Use Caution/Monitor.
- amisulpride
amisulpride and dimenhydrinate both increase sedation. Use Caution/Monitor.
- amitriptyline
dimenhydrinate and amitriptyline both increase sedation. Use Caution/Monitor.
- amobarbital
dimenhydrinate and amobarbital both increase sedation. Use Caution/Monitor.
- amoxapine
dimenhydrinate and amoxapine both increase sedation. Use Caution/Monitor.
- apomorphine
dimenhydrinate and apomorphine both increase sedation. Use Caution/Monitor.
- arformoterol
dimenhydrinate increases and arformoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- aripiprazole
dimenhydrinate and aripiprazole both increase sedation. Use Caution/Monitor.
- armodafinil
dimenhydrinate increases and armodafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- asenapine
asenapine and dimenhydrinate both increase sedation. Use Caution/Monitor.
- asenapine transdermal
asenapine transdermal and dimenhydrinate both increase sedation. Use Caution/Monitor.
- avapritinib
avapritinib and dimenhydrinate both increase sedation. Use Caution/Monitor.
- azelastine
azelastine and dimenhydrinate both increase sedation. Use Caution/Monitor.
- baclofen
dimenhydrinate and baclofen both increase sedation. Use Caution/Monitor.
- belladonna and opium
dimenhydrinate and belladonna and opium both increase sedation. Use Caution/Monitor.
- benperidol
dimenhydrinate and benperidol both increase sedation. Use Caution/Monitor.
- benzhydrocodone/acetaminophen
benzhydrocodone/acetaminophen and dimenhydrinate both increase sedation. Use Caution/Monitor.
- benzphetamine
dimenhydrinate increases and benzphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- benztropine
dimenhydrinate increases toxicity of benztropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects.
- brexanolone
brexanolone, dimenhydrinate. Either increases toxicity of the other by sedation. Use Caution/Monitor.
- brexpiprazole
brexpiprazole and dimenhydrinate both increase sedation. Use Caution/Monitor.
- brimonidine
brimonidine and dimenhydrinate both increase sedation. Use Caution/Monitor.
- brivaracetam
brivaracetam and dimenhydrinate both increase sedation. Use Caution/Monitor.
- brompheniramine
brompheniramine and dimenhydrinate both increase sedation. Use Caution/Monitor.
- buprenorphine
dimenhydrinate and buprenorphine both increase sedation. Use Caution/Monitor.
- buprenorphine buccal
dimenhydrinate and buprenorphine buccal both increase sedation. Use Caution/Monitor.
- buprenorphine subdermal implant
buprenorphine subdermal implant and dimenhydrinate both increase sedation. Use Caution/Monitor.
- buprenorphine transdermal
buprenorphine transdermal and dimenhydrinate both increase sedation. Use Caution/Monitor.
- butabarbital
dimenhydrinate and butabarbital both increase sedation. Use Caution/Monitor.
- butalbital
dimenhydrinate and butalbital both increase sedation. Use Caution/Monitor.
- butorphanol
dimenhydrinate and butorphanol both increase sedation. Use Caution/Monitor.
- caffeine
dimenhydrinate increases and caffeine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- carbinoxamine
carbinoxamine and dimenhydrinate both increase sedation. Use Caution/Monitor.
- carisoprodol
dimenhydrinate and carisoprodol both increase sedation. Use Caution/Monitor.
- chloral hydrate
dimenhydrinate and chloral hydrate both increase sedation. Use Caution/Monitor.
- chlordiazepoxide
dimenhydrinate and chlordiazepoxide both increase sedation. Use Caution/Monitor.
- chlorpheniramine
chlorpheniramine and dimenhydrinate both increase sedation. Use Caution/Monitor.
- chlorpromazine
dimenhydrinate and chlorpromazine both increase sedation. Use Caution/Monitor.
- chlorzoxazone
dimenhydrinate and chlorzoxazone both increase sedation. Use Caution/Monitor.
- cinnarizine
cinnarizine and dimenhydrinate both increase sedation. Use Caution/Monitor.
- clemastine
clemastine and dimenhydrinate both increase sedation. Use Caution/Monitor.
- clobazam
dimenhydrinate, clobazam. Other (see comment). Use Caution/Monitor. Comment: Concomitant administration can increase the potential for CNS effects (e.g., increased sedation or respiratory depression).
- clomipramine
dimenhydrinate and clomipramine both increase sedation. Use Caution/Monitor.
- clonazepam
dimenhydrinate and clonazepam both increase sedation. Use Caution/Monitor.
- clorazepate
dimenhydrinate and clorazepate both increase sedation. Use Caution/Monitor.
- clozapine
dimenhydrinate and clozapine both increase sedation. Use Caution/Monitor.
- codeine
dimenhydrinate and codeine both increase sedation. Use Caution/Monitor.
- cyclizine
cyclizine and dimenhydrinate both increase sedation. Use Caution/Monitor.
- cyclobenzaprine
dimenhydrinate and cyclobenzaprine both increase sedation. Use Caution/Monitor.
- cyproheptadine
cyproheptadine and dimenhydrinate both increase sedation. Use Caution/Monitor.
- dantrolene
dimenhydrinate and dantrolene both increase sedation. Use Caution/Monitor.
- daridorexant
dimenhydrinate and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment.
- desflurane
desflurane and dimenhydrinate both increase sedation. Use Caution/Monitor.
- desipramine
dimenhydrinate and desipramine both increase sedation. Use Caution/Monitor.
- deutetrabenazine
dimenhydrinate and deutetrabenazine both increase sedation. Use Caution/Monitor.
- dexchlorpheniramine
dexchlorpheniramine and dimenhydrinate both increase sedation. Use Caution/Monitor.
- dexfenfluramine
dimenhydrinate increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dexmedetomidine
dimenhydrinate and dexmedetomidine both increase sedation. Use Caution/Monitor.
- dexmethylphenidate
dimenhydrinate increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dextroamphetamine
dimenhydrinate increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dextromoramide
dimenhydrinate and dextromoramide both increase sedation. Use Caution/Monitor.
- diamorphine
dimenhydrinate and diamorphine both increase sedation. Use Caution/Monitor.
- diazepam
dimenhydrinate and diazepam both increase sedation. Use Caution/Monitor.
- diazepam intranasal
diazepam intranasal, dimenhydrinate. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration may potentiate the CNS-depressant effects of each drug.
- diethylpropion
dimenhydrinate increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- difelikefalin
difelikefalin and dimenhydrinate both increase sedation. Use Caution/Monitor.
- difenoxin hcl
dimenhydrinate and difenoxin hcl both increase sedation. Use Caution/Monitor.
- diphenhydramine
dimenhydrinate and diphenhydramine both increase sedation. Use Caution/Monitor.
- diphenoxylate hcl
dimenhydrinate and diphenoxylate hcl both increase sedation. Use Caution/Monitor.
- dipipanone
dimenhydrinate and dipipanone both increase sedation. Use Caution/Monitor.
- dobutamine
dimenhydrinate increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- donepezil transdermal
donepezil transdermal, dimenhydrinate. Either decreases effects of the other by pharmacodynamic antagonism. Use Caution/Monitor.
- dopamine
dimenhydrinate increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dopexamine
dimenhydrinate increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- dosulepin
dimenhydrinate and dosulepin both increase sedation. Use Caution/Monitor.
- doxepin
dimenhydrinate and doxepin both increase sedation. Use Caution/Monitor.
- doxylamine
dimenhydrinate and doxylamine both increase sedation. Use Caution/Monitor.
- droperidol
dimenhydrinate and droperidol both increase sedation. Use Caution/Monitor.
- ephedrine
dimenhydrinate increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- epinephrine
dimenhydrinate increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- epinephrine racemic
dimenhydrinate increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- esketamine intranasal
esketamine intranasal, dimenhydrinate. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.
- estazolam
dimenhydrinate and estazolam both increase sedation. Use Caution/Monitor.
- ethanol
dimenhydrinate and ethanol both increase sedation. Use Caution/Monitor.
- etomidate
etomidate and dimenhydrinate both increase sedation. Use Caution/Monitor.
- fenfluramine
dimenhydrinate increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- fentanyl
fentanyl, dimenhydrinate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.
- fentanyl intranasal
fentanyl intranasal, dimenhydrinate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.
- fentanyl transdermal
fentanyl transdermal, dimenhydrinate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.
- fentanyl transmucosal
fentanyl transmucosal, dimenhydrinate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of fentanyl with anticholinergics may increase risk for urinary retention and/or severe constipation, which may lead to paralytic ileus.
- flibanserin
dimenhydrinate and flibanserin both increase sedation. Modify Therapy/Monitor Closely. Risk for sedation increased if flibanserin is coadministration with other CNS depressants.
- fluphenazine
dimenhydrinate and fluphenazine both increase sedation. Use Caution/Monitor.
- flurazepam
dimenhydrinate and flurazepam both increase sedation. Use Caution/Monitor.
- formoterol
dimenhydrinate increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- gabapentin
gabapentin, dimenhydrinate. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- gabapentin enacarbil
gabapentin enacarbil, dimenhydrinate. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- ganaxolone
dimenhydrinate and ganaxolone both increase sedation. Use Caution/Monitor.
- glycopyrronium tosylate topical
glycopyrronium tosylate topical, dimenhydrinate. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.
- gotu kola
gotu kola increases effects of dimenhydrinate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- haloperidol
dimenhydrinate and haloperidol both increase sedation. Use Caution/Monitor.
- hawthorn
hawthorn increases effects of dimenhydrinate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- hops
hops increases effects of dimenhydrinate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- hyaluronidase
dimenhydrinate decreases effects of hyaluronidase by Other (see comment). Use Caution/Monitor. Comment: Antihistamines, when given in large systemic doses, may render tissues partially resistant to the action of hyaluronidase. Patients may require larger amounts of hyaluronidase for equivalent dispersing effect.
- hydromorphone
dimenhydrinate and hydromorphone both increase sedation. Use Caution/Monitor.
- hydroxyzine
dimenhydrinate and hydroxyzine both increase sedation. Use Caution/Monitor.
- iloperidone
dimenhydrinate and iloperidone both increase sedation. Use Caution/Monitor.
- imipramine
dimenhydrinate and imipramine both increase sedation. Use Caution/Monitor.
- incobotulinumtoxinA
dimenhydrinate, incobotulinumtoxinA. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Use of anticholinergic drugs after administration of botulinum toxin-containing products may potentiate systemic anticholinergic effects.
- isoproterenol
dimenhydrinate increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- kava
kava increases effects of dimenhydrinate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- ketamine
ketamine and dimenhydrinate both increase sedation. Use Caution/Monitor.
- ketotifen, ophthalmic
dimenhydrinate and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.
- lasmiditan
lasmiditan, dimenhydrinate. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.
- lemborexant
lemborexant, dimenhydrinate. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.
- levalbuterol
dimenhydrinate increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- levorphanol
dimenhydrinate and levorphanol both increase sedation. Use Caution/Monitor.
- lisdexamfetamine
dimenhydrinate increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- lofepramine
dimenhydrinate and lofepramine both increase sedation. Use Caution/Monitor.
- lofexidine
dimenhydrinate and lofexidine both increase sedation. Use Caution/Monitor.
- loprazolam
dimenhydrinate and loprazolam both increase sedation. Use Caution/Monitor.
- lorazepam
dimenhydrinate and lorazepam both increase sedation. Use Caution/Monitor.
- lormetazepam
dimenhydrinate and lormetazepam both increase sedation. Use Caution/Monitor.
- loxapine
dimenhydrinate and loxapine both increase sedation. Use Caution/Monitor.
- loxapine inhaled
dimenhydrinate and loxapine inhaled both increase sedation. Use Caution/Monitor.
- lurasidone
lurasidone, dimenhydrinate. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.
- maprotiline
dimenhydrinate and maprotiline both increase sedation. Use Caution/Monitor.
- marijuana
dimenhydrinate and marijuana both increase sedation. Use Caution/Monitor.
- melatonin
dimenhydrinate and melatonin both increase sedation. Use Caution/Monitor.
- meperidine
dimenhydrinate and meperidine both increase sedation. Use Caution/Monitor.
- meprobamate
dimenhydrinate and meprobamate both increase sedation. Use Caution/Monitor.
- metaproterenol
dimenhydrinate increases and metaproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- metaxalone
dimenhydrinate and metaxalone both increase sedation. Use Caution/Monitor.
- methadone
dimenhydrinate and methadone both increase sedation. Use Caution/Monitor.
- methamphetamine
dimenhydrinate increases and methamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- methocarbamol
dimenhydrinate and methocarbamol both increase sedation. Use Caution/Monitor.
- methylenedioxymethamphetamine
dimenhydrinate increases and methylenedioxymethamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- midazolam
dimenhydrinate and midazolam both increase sedation. Use Caution/Monitor.
- midazolam intranasal
midazolam intranasal, dimenhydrinate. Either increases toxicity of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Concomitant use of barbiturates, alcohol, or other CNS depressants may increase risk of hypoventilation, airway obstruction, desaturation, or apnea and may contribute to profound and/or prolonged drug effect.
- midodrine
dimenhydrinate increases and midodrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- mirtazapine
dimenhydrinate and mirtazapine both increase sedation. Use Caution/Monitor.
- modafinil
dimenhydrinate increases and modafinil decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- morphine
dimenhydrinate and morphine both increase sedation. Use Caution/Monitor.
- motherwort
dimenhydrinate and motherwort both increase sedation. Use Caution/Monitor.
- moxonidine
dimenhydrinate and moxonidine both increase sedation. Use Caution/Monitor.
- nabilone
dimenhydrinate and nabilone both increase sedation. Use Caution/Monitor.
- nalbuphine
dimenhydrinate and nalbuphine both increase sedation. Use Caution/Monitor.
- norepinephrine
dimenhydrinate increases and norepinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- nortriptyline
dimenhydrinate and nortriptyline both increase sedation. Use Caution/Monitor.
- olanzapine
dimenhydrinate and olanzapine both increase sedation. Use Caution/Monitor.
- opium tincture
dimenhydrinate and opium tincture both increase sedation. Use Caution/Monitor.
- orphenadrine
dimenhydrinate and orphenadrine both increase sedation. Use Caution/Monitor.
- oxazepam
dimenhydrinate and oxazepam both increase sedation. Use Caution/Monitor.
- oxycodone
dimenhydrinate and oxycodone both increase sedation. Use Caution/Monitor.
- oxymorphone
dimenhydrinate and oxymorphone both increase sedation. Use Caution/Monitor.
- paliperidone
dimenhydrinate and paliperidone both increase sedation. Use Caution/Monitor.
- papaveretum
dimenhydrinate and papaveretum both increase sedation. Use Caution/Monitor.
- papaverine
dimenhydrinate and papaverine both increase sedation. Use Caution/Monitor.
- passion flower
passion flower increases effects of dimenhydrinate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- pentazocine
dimenhydrinate and pentazocine both increase sedation. Use Caution/Monitor.
- pentobarbital
dimenhydrinate and pentobarbital both increase sedation. Use Caution/Monitor.
- perphenazine
dimenhydrinate and perphenazine both increase sedation. Use Caution/Monitor.
- phendimetrazine
dimenhydrinate increases and phendimetrazine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenobarbital
dimenhydrinate and phenobarbital both increase sedation. Use Caution/Monitor.
- phentermine
dimenhydrinate increases and phentermine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine
dimenhydrinate increases and phenylephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- phenylephrine PO
dimenhydrinate increases and phenylephrine PO decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor. .
- pholcodine
dimenhydrinate and pholcodine both increase sedation. Use Caution/Monitor.
- pimozide
dimenhydrinate and pimozide both increase sedation. Use Caution/Monitor.
- pirbuterol
dimenhydrinate increases and pirbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- pregabalin
pregabalin, dimenhydrinate. Either increases effects of the other by pharmacodynamic synergism. Modify Therapy/Monitor Closely. Coadministration of CNS depressants can result in serious, life-threatening, and fatal respiratory depression. Use lowest dose possible and monitor for respiratory depression and sedation.
- primidone
dimenhydrinate and primidone both increase sedation. Use Caution/Monitor.
- prochlorperazine
dimenhydrinate and prochlorperazine both increase sedation. Use Caution/Monitor.
- promethazine
dimenhydrinate and promethazine both increase sedation. Use Caution/Monitor.
- propofol
propofol and dimenhydrinate both increase sedation. Use Caution/Monitor.
- propylhexedrine
dimenhydrinate increases and propylhexedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- protriptyline
dimenhydrinate and protriptyline both increase sedation. Use Caution/Monitor.
- quazepam
dimenhydrinate and quazepam both increase sedation. Use Caution/Monitor.
- quetiapine
dimenhydrinate and quetiapine both increase sedation. Use Caution/Monitor.
- ramelteon
dimenhydrinate and ramelteon both increase sedation. Use Caution/Monitor.
- rimabotulinumtoxinB
dimenhydrinate, rimabotulinumtoxinB. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Anticholinergics may enhance botulinum toxin effects. Closely monitor for increased neuromuscular blockade.
- risperidone
dimenhydrinate and risperidone both increase sedation. Use Caution/Monitor.
- salmeterol
dimenhydrinate increases and salmeterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- scullcap
dimenhydrinate and scullcap both increase sedation. Use Caution/Monitor.
- secobarbital
dimenhydrinate and secobarbital both increase sedation. Use Caution/Monitor.
- sevoflurane
sevoflurane and dimenhydrinate both increase sedation. Use Caution/Monitor.
- shepherd's purse
dimenhydrinate and shepherd's purse both increase sedation. Use Caution/Monitor.
- stiripentol
stiripentol, dimenhydrinate. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.
- sufentanil
dimenhydrinate and sufentanil both increase sedation. Use Caution/Monitor.
- tapentadol
dimenhydrinate and tapentadol both increase sedation. Use Caution/Monitor.
- temazepam
dimenhydrinate and temazepam both increase sedation. Use Caution/Monitor.
- terbutaline
dimenhydrinate increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- thioridazine
dimenhydrinate and thioridazine both increase sedation. Use Caution/Monitor.
- thiothixene
dimenhydrinate and thiothixene both increase sedation. Use Caution/Monitor.
- topiramate
dimenhydrinate and topiramate both increase sedation. Modify Therapy/Monitor Closely.
- tramadol
dimenhydrinate and tramadol both increase sedation. Use Caution/Monitor.
- trazodone
dimenhydrinate and trazodone both increase sedation. Use Caution/Monitor.
- triazolam
dimenhydrinate and triazolam both increase sedation. Use Caution/Monitor.
- triclofos
dimenhydrinate and triclofos both increase sedation. Use Caution/Monitor.
- trifluoperazine
dimenhydrinate and trifluoperazine both increase sedation. Use Caution/Monitor.
- trihexyphenidyl
dimenhydrinate increases toxicity of trihexyphenidyl by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects.
- trimipramine
dimenhydrinate and trimipramine both increase sedation. Use Caution/Monitor.
- triprolidine
dimenhydrinate and triprolidine both increase sedation. Use Caution/Monitor.
- valerian
valerian increases effects of dimenhydrinate by pharmacodynamic synergism. Use Caution/Monitor. May enhance CNS depression.
- xylometazoline
dimenhydrinate increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- yohimbine
dimenhydrinate increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.
- ziconotide
dimenhydrinate and ziconotide both increase sedation. Use Caution/Monitor.
- ziprasidone
dimenhydrinate and ziprasidone both increase sedation. Use Caution/Monitor.
- zotepine
dimenhydrinate and zotepine both increase sedation. Use Caution/Monitor.
Minor (45)
- aclidinium
dimenhydrinate increases toxicity of aclidinium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- anticholinergic/sedative combos
dimenhydrinate increases toxicity of anticholinergic/sedative combos by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- ashwagandha
ashwagandha increases effects of dimenhydrinate by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.
- atracurium
dimenhydrinate increases toxicity of atracurium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- atropine
dimenhydrinate increases toxicity of atropine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- atropine IV/IM
dimenhydrinate increases toxicity of atropine IV/IM by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- belladonna alkaloids
dimenhydrinate increases toxicity of belladonna alkaloids by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- belladonna and opium
dimenhydrinate increases toxicity of belladonna and opium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- brimonidine
brimonidine increases effects of dimenhydrinate by pharmacodynamic synergism. Minor/Significance Unknown. Increased CNS depression.
- cisatracurium
dimenhydrinate increases toxicity of cisatracurium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- cyclizine
dimenhydrinate increases toxicity of cyclizine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- cyclobenzaprine
dimenhydrinate increases toxicity of cyclobenzaprine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- darifenacin
dimenhydrinate increases toxicity of darifenacin by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- dicyclomine
dimenhydrinate increases toxicity of dicyclomine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- diphenhydramine
dimenhydrinate increases toxicity of diphenhydramine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- eucalyptus
dimenhydrinate and eucalyptus both increase sedation. Minor/Significance Unknown.
- fesoterodine
dimenhydrinate increases toxicity of fesoterodine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- flavoxate
dimenhydrinate increases toxicity of flavoxate by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- glycopyrrolate
dimenhydrinate increases toxicity of glycopyrrolate by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- glycopyrrolate inhaled
dimenhydrinate increases toxicity of glycopyrrolate inhaled by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- henbane
dimenhydrinate increases toxicity of henbane by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- homatropine
dimenhydrinate increases toxicity of homatropine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- hyoscyamine
dimenhydrinate increases toxicity of hyoscyamine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- hyoscyamine spray
dimenhydrinate increases toxicity of hyoscyamine spray by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- ipratropium
dimenhydrinate increases toxicity of ipratropium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- meclizine
dimenhydrinate increases toxicity of meclizine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- methscopolamine
dimenhydrinate increases toxicity of methscopolamine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- nettle
nettle increases effects of dimenhydrinate by pharmacodynamic synergism. Minor/Significance Unknown. (High dose nettle; theoretical interaction) May enhance CNS depression.
- onabotulinumtoxinA
dimenhydrinate increases toxicity of onabotulinumtoxinA by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- oxybutynin
dimenhydrinate increases toxicity of oxybutynin by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- oxybutynin topical
dimenhydrinate increases toxicity of oxybutynin topical by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- oxybutynin transdermal
dimenhydrinate increases toxicity of oxybutynin transdermal by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- pancuronium
dimenhydrinate increases toxicity of pancuronium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- pralidoxime
dimenhydrinate increases toxicity of pralidoxime by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- propantheline
dimenhydrinate increases toxicity of propantheline by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- rapacuronium
dimenhydrinate increases toxicity of rapacuronium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- rocuronium
dimenhydrinate increases toxicity of rocuronium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- sage
dimenhydrinate and sage both increase sedation. Minor/Significance Unknown.
- scopolamine
dimenhydrinate increases toxicity of scopolamine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- Siberian ginseng
Siberian ginseng increases effects of dimenhydrinate by pharmacodynamic synergism. Minor/Significance Unknown. May enhance CNS depression.
- solifenacin
dimenhydrinate increases toxicity of solifenacin by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- tiotropium
dimenhydrinate increases toxicity of tiotropium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- tolterodine
dimenhydrinate increases toxicity of tolterodine by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- trospium chloride
dimenhydrinate increases toxicity of trospium chloride by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
- vecuronium
dimenhydrinate increases toxicity of vecuronium by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.
Adverse Effects
Varies in incidence and severity with the individual drug; also individual patients vary in susceptibility
Frequency Not Defined
Paradoxical CNS stimulation (children and occasionally in adults)
CNS depression
Drowsiness
Sedation ranging from mild drowsiness to deep sleep (most frequent)
Dizziness
Lassitude
Disturbed coordination
Muscular weakness
Restlessness, insomnia, tremors, euphoria, nervousness, delirium, palpitation, seizures is less common
Epigastric distress
Anorexia
Nausea
Vomiting
Diarrhea
Constipation
Cholestasis, hepatitis, hepatic failure, hepatic function abnormality, jaundice is rare
Eczema, pruritus, inflammation, papular rash, erythema on exposed skin may occur with topical formulation
Tachycardia, palpitation ECG changes (eg, widened QRS)
Arrhythmias (eg, extrasystole, heart block)
Hypotension
Hypertension
Dizziness, sedation, and hypotension may occur in geriatric patients
Dryness of mouth, nose, and throat
Dysuria
Urinary retention
Impotence
Vertigo
Visual disturbances
Blurred vision
Diplopia; tinnitus
Acute labyrinthitis
Insomnia
Tremors
Nervousness
Irritability
Facial dyskinesia
Tightness of the chest
Thickening of bronchial secretions
Wheezing
Nasal stuffiness
Sweating
Chills
Early menses
Toxic psychosis
Headache
Faintness
Paresthesia
Agranulocytosis
Hemolytic anemia
Leukopenia
Thrombocytopenia
Pancytopenia
Warnings
Contraindications
Documented hypersensitivity to dimenhydrinate or diphenhydramine
Lower respiratory disease, eg, asthma (controversial)
Preemies and neonates
Nursing women
Cautions
May impair ability to drive or operate heavy machinery
May mask early signs of ototoxicity if given concomitantly with ototoxic drugs (eg, aminoglycosides)
Patients with seizures, angle-closure glaucoma, enlargement of prostate gland, asthma, emphysema, acute hepatic insufficiency
Pregnancy & Lactation
Pregnancy Category: B
Lactation: Crosses into breast milk, discontinue drug or do not nurse
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Ethanolamine H1 antagonist containing diphenhydramine and 8-chloro-theophylline; pharmacological effects principally result from diphenhydramine moiety, has CNS depressant, anticholinergic, antiemetic, antihistamine, and local anesthetic effects
Antiemetic action may result from inhibiting vestibular stimulation, and inhibiting acetylcholine
Pharmacokinetics
Half-Life: unknown, (half-life of diphenhydramine is about 3.5 hr)
Duration: 3-6 hr
Onset: 20-30 min (IM); 15-30 min (PO); almost immediately (IV)
Bioavailability: Well absorbed
Metabolism: Extensively metabolized in the liver, based on data for diphenhydramine
Excretion: Principally in urine (as metabolites)
Administration
IV Compatibilities
Solution: compatible with most common solvents
Additive: amikacin, amobarbital (at 1 g amobarbital/500 mg dimenhydrinate), calcium gluconate, chloramphenicol sodium succinate, corticotropin, heparin, hydroxyzine, norepinephrine, penicillin G, pentobarbital, phenobarbital, KCl, prochlorperazine, vancomycin, vitamin B/C
Syringe: atropine, codeine, diatrizoate meglumine, diatrizoate sodium, diphenhydramine, droperidol, fentanyl, heparin, hydromorphone, hyoscine, iothalamate meglumine, iothalamate sodium, meperidine, metoclopramide, morphine, pentazocine, perphenazine, ranitidine, scopolamine
Y-site: acyclovir
IV Incompatibilities
Additive: aminophylline (at 1g/L aminophylline and 500 mg/L dimenhydrinate; may be compatible at lower conc), ammonium chloride(?), hydrocortisone (at 500 mg hydrocortisone and 500 mg dimenhydrinate; may be compatible at lower conc), thiopental
Syringe: butorphanol, chlorpromazine, glycopyrrolate, hydroxyzine, iodipamide, midazolam, nalbuphine, papaveretum, pentobarbital, prochlorperazine, promazine, promethazine, thiopental
IV Administration
50 mg in 10 mL NS over 2 min
Storage
Do not use if cloudy or contains a precipitate
Store at controlled room temp 15-30°C
Protect from freezing
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| Driminate oral - | 50 mg tablet |  | |
| Driminate oral - | 50 mg tablet |  | |
| Motion Sickness Relief oral - | 50 mg tablet | | |
| Motion Sickness Relief oral - | 50 mg tablet | |
Copyright © 2010 First DataBank, Inc.
Patient Handout
dimenhydrinate injection
DIMENHYDRINATE - INJECTION
(DYE-men-HYE-dri-nate)
COMMON BRAND NAME(S): Dramamine
USES: Dimenhydrinate is an antihistamine used to prevent and treat nausea, vomiting and dizziness caused by motion sickness when medication cannot be given by mouth.Dimenhydrinate injection should not be used in newborns because of an increased risk of side effects.
HOW TO USE: This medication is injected into a vein (IV), or it can be injected into a muscle by a health care professional, as directed by your doctor. Your dosage is based on your medical condition and response to therapy.Tell your doctor if your condition lasts or gets worse.
SIDE EFFECTS: Drowsiness, constipation, blurred vision, or dry mouth/nose/throat may occur. If any of these effects last or get worse, tell your doctor or pharmacist promptly.To relieve dry mouth, suck on (sugarless) hard candy or ice chips, chew (sugarless) gum, drink water or use a saliva substitute.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.Tell your doctor right away if you have any serious side effects, including: mental/mood changes (such as restlessness, confusion), fast/irregular heartbeat, shaking (tremor), difficulty urinating.Get medical help right away if you have any very serious side effects, including: seizures.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before using dimenhydrinate, tell your doctor or pharmacist if you are allergic to it; or to diphenhydramine; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: breathing problems (such as asthma, emphysema), glaucoma, stomach problems (such as ulcers, obstruction), difficulty urinating (for example, due to an enlarged prostate gland), heart disease, high blood pressure, liver disease, seizures, overactive thyroid.This drug may make you drowsy or blur your vision. Alcohol or marijuana (cannabis) can make you more drowsy. Do not drive, use machinery, or do anything that needs alertness or clear vision until you can do it safely. Avoid alcoholic beverages. Talk to your doctor if you are using marijuana (cannabis).Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).Children may be more sensitive to the side effects of this drug. This drug can often cause excitement in young children instead of drowsiness.Older adults may be more sensitive to the side effects of this drug, especially drowsiness, confusion, constipation, or trouble urinating. Drowsiness and confusion can increase the risk of falling.During pregnancy, this medication should be used only when clearly needed. Discuss the risks and benefits with your doctor.This drug passes into breast milk and may have undesirable effects on a nursing infant. Consult your doctor before breast-feeding.
DRUG INTERACTIONS: Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.Some products that may interact with this drug include: antihistamines applied to the skin (such as diphenhydramine cream, ointment, spray).Tell your doctor or pharmacist if you are taking other products that cause drowsiness such as opioid pain or cough relievers (such as codeine, hydrocodone), alcohol, marijuana (cannabis), drugs for sleep or anxiety (such as alprazolam, lorazepam, zolpidem), muscle relaxants (such as carisoprodol, cyclobenzaprine), or other antihistamines (such as cetirizine, diphenhydramine).Check the labels on all your medicines (such as allergy or cough-and-cold products) because they may contain ingredients that cause drowsiness. Ask your pharmacist about using those products safely.This medication may interfere with certain laboratory tests (including allergy skin test), possibly causing false test results. Make sure laboratory personnel and all your doctors know you use this drug.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center. Symptoms of overdose may include: severe drowsiness, seizures, widened pupils. In children, mental/mood changes (such as restlessness, irritability, hallucinations) may occur before drowsiness.
NOTES: Do not share this product with others.
MISSED DOSE: It is important to get each dose of this medication as scheduled. If you miss a dose, ask your doctor or pharmacist right away for a new dosing schedule.
STORAGE: Not applicable. This medication is given in a hospital or clinic and will not be stored at home.
Information last revised March 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
